In acute treatment , the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale ( ABC-I ) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group .
According to the discontinuation phase , the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group .
The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments .
Conclusion In relation to the current systematic review , risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD .
Although its acceptability is comparable to placebo , treatment with risperidone is well tolerated in children and adolescents with ASD
Background Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder ( ASD ) in children and adolescents .
Objective The aim of this systematic review was to determine the efficacy , acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD .
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
BACKGROUND Neurobiological research has implicated the dopamine and serotonin systems in the pathogenesis of autism . Open-label reports suggest that the serotonin2A-dopamine D2 antagonist risperidone may be safe and effective in reducing the interfering symptoms of patients with autism . METHODS Thirty-one adults ( age [ mean+/-SD ] , 28.1+/-7.3 years ) with autistic disorder ( n=17 ) or pervasive developmental disorder not otherwise specified ( n=14 ) participated in a 12-week double-blind ,  placebo-controlled trial of risperidone . Patients treated with placebo subsequently received a 12-week open-label trial of risperidone . RESULTS For persons completing the study , 8 ( 57 % ) of 14 patients treated with risperidone were categorized as responders ( daily dose [ mean+/-SD ] , 2.9+/-1.4 mg ) compared with none of 16 in the placebo group ( P<.002 ) . Risperidone was superior to placebo in reducing repetitive behavior ( P<.001 ) , aggression ( P<.001 ) , anxiety or nervousness ( P<.02 ) , depression ( P<.03 ) , irritability ( P<.01 ) , and the overall behavioral symptoms of autism ( P<.02 ) . Objective , measurable change in social behavior and language did not occur . Nine ( 60 % ) of 15 patients who received treatment with open-label risperidone following the double-blind placebo phase responded . Other than mild , transient sedation , risperidone was well tolerated , with no evidence of extrapyramidal effects , cardiac events , or seizures . CONCLUSION Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults
In acute treatment , the pooled mean change score of the Aberrant Behavior Checklist for irritability subscale ( ABC-I ) and response rate for the risperidone-treated group had a greater significance than that of the placebo-treated group .
According to the discontinuation phase , the overall pooled relapse rate of the risperidone-treated group was significantly less than that of the placebo-treated group .
The rates of pooled overall discontinuation and discontinuation due to adverse events rates were not different between the two groups in acute and long-term treatments .
Conclusion In relation to the current systematic review , risperidone is efficacious in the treatment of symptoms in children and adolescents with ASD .
Although its acceptability is comparable to placebo , treatment with risperidone is well tolerated in children and adolescents with ASD
Background Various clinical trials suggested that risperidone was beneficial in the treatment of autism spectrum disorder ( ASD ) in children and adolescents .
Objective The aim of this systematic review was to determine the efficacy , acceptability and tolerability of risperidone in the treatment of children and adolescents with ASD .